A Phase II Study of Anlotinib and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Lung Cancer.

NCT07307443 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

28

Enrollment

OTHER

Sponsor class

Conditions

SMARCA4-Deficient Tumor
Locally Advanced or Metastatic Lung Cancer

Interventions

DRUG: Anlotinib, nab-paclitaxel, carboplatin

Sponsor

Zhijie Wang

Collaborators

[object Object]
[object Object]